Abstract:KEYWORDS: The mitochondrial permeability transition (MPT) is defined as the loss of inner membrane a specific impermeability and transmembrane potential, due to the sustained opening of a large pore (the MPTP). The pore (also nicknamed Mitochondrial MegaChannel, MMC) has been characterized decades ago in studies with isolated mitochondria and – by our group – by single-channel patch-clamp on rat liver mitoplasts. Very similar activity (the Multi-Conductance Channel, MCC) was independently described by K.W. Kinnally's group (revs [ Citation 1 , Citation 2 ]). The awakening of this megachannel is elicited by increases in matrix Ca 2+ levels and is potentiated by other agents/processes, the major one being oxidative stress. The equivalent diameter of the pore can be as large as 3 nm but the channel exhibits a variety of sizes. In samples of isolated mitochondria, the molecular weight of permeating molecules increases as a function of the inducing Ca 2+ concentration and of the time elapsed since induction. Partial removal of the OMM would instead tend to decrease it [ Citation 3 ]. Prolonged opening is accompanied by depolarization, release of matrix components, further generation of reactive oxygen species (ROS), morphological changes (swelling, fragmentation of the mitochondrial network), decrease in cellular ATP levels, activation of mitophagy and, eventually, cell death. MPTP opening has been proposed to be involved in ischemia/reperfusion injury (IRI), aging and aging-associated neurodegenerative diseases, chronic stress syndrome, traumatic brain injury, muscular dystrophy, diabetes, cirrhosis, pancreatitis, osteoporosis, and more. In addition, cancer cells deploy desensitization mechanisms which help cancer growth and dispersion, and which may oppose chemotherapy. Inhibiting or activating the MPTP is therefore an exceptionally relevant pharmacological goal. As such, it has received much attention, but so far successes in pre-clinical models have not been accompanied by a proportionate impact in clinical practice. The effort continues. The MPTP is also believed to have physiological and protective roles under normal circumstances, by opening transiently to act as a 'Ca 2+ release valve,' preventing mitochondrial Ca 2+ overload, and tuning mitochondrial function [ Citation 4 , Citation 5 ]. This function appears to be particularly important in cardiac myocytes.

Defining the molecular mechanisms of the mitochondrial permeability transition through genetic manipulation of F-ATP synthase

Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions

ATP synthase c-subunit ring as the channel of mitochondrial permeability transition: Regulator of metabolism in development and degeneration

Mitochondrial Permeability Transition in Stem Cells, Development, and Disease

The mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore

Refractive Index Imaging Reveals That Elimination of the ATP Synthase C Subunit Does Not Prevent the Adenine Nucleotide Translocase-Dependent Mitochondrial Permeability Transition

Mitochondrial permeability transition pore: a snapshot of a therapeutic target

The mitochondrial permeability transition pore: an evolving concept critical for cell life and death

Investigation of Properties of the Mitochondrial Permeability Transition Pore Using Whole-Mitoplast Patch-Clamp Technique

Induction of the permeability transition pore in cells depleted of mitochondrial DNA

The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation

Competitive interaction between ATP and GTP regulates mitochondrial ATP-sensitive potassium channels

Modulation of mitochondrial permeability transition pores in reperfusion injury: Mechanisms and therapeutic approaches

A mitochondrial megachannel resides in monomeric F1FO ATP synthase

Mitochondrial Megachannel Resides in Monomeric ATP Synthase

Mitochondrial ATP synthase c-subunit leak channel triggers cell death upon loss of its F1 subcomplex

Targeting the mitochondrial permeability transition pore for drug discovery: Challenges and opportunities

The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis

Mitochondrial permeability transition mediated by MTCH2 and F‐ATP synthase contributes to ferroptosis defense

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Development or disease: duality of the mitochondrial permeability transition pore